Abiraterone acetate , an androgen biosynthesis inhibitor , prolongs survival in men with metastatic castration-resistant prostate cancer ( mCRPC ) in the pre - and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302 .